Determination of the new aromatase inhibitor CGS 16 949 in biological fluids by capillary gas chromatography/mass spectrometry.
A specific and sensitive gas chromatographic/mass spectrometric method was developed and validated for the quantitative determination of the aromatase inhibitor CGS 16 949 in plasma and urine. A deuterium-labelled analogue of CGS 16 949 was used as internal standard. The analysis of spiked samples demonstrated the good accuracy and precision of the method. For both plasma and urine, the limit of quantification (LOQ: coefficient of variation (CV) = 10%) and the limit of detection (LOD: CV = 100%) were estimated to be 5 and 1 nmol l-1, respectively. The method was applied to the determination of unchanged CGS 16 949 in plasma and urine of a healthy volunteer orally dosed with 1 mg of CGS 16 949 A.
Ackermann
R
R
Ciba-Geigy Ltd, Pharmaceuticals Division, Basle, Switzerland.
Kaiser
G
G
D047072:Aromatase Inhibitors; D017316:Fadrozole; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D007093:Imidazoles / Q000032:analysis* / Q000493:pharmacokinetics; D008297:Male; D009570:Nitriles / Q000493:pharmacokinetics
D047072:Aromatase Inhibitors; D007093:Imidazoles; D009570:Nitriles; D017316:Fadrozole